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Abstract
Purpose To identify the qualitative evidence on the experience of cancer and comorbid illness from the perspective of patients,
carers and health care professionals to identify psycho-social support needs, experience of health care, and to highlight areas
where more research is needed.
Methods A qualitative systematic review following PRISMA guidance. Relevant research databases were searched using an
exhaustive list of search terms. Two reviewers independently screened titles and abstracts and discussed variations. Included
articles were subject to quality appraisal before data extraction of article characteristics and findings. Thomas and Harden’s
thematic synthesis of extracted findings was undertaken.
Results Thirty-one articles were included in the review, covering a range of cancer types and comorbid conditions; with varying time
since cancer diagnosis and apparent severity of disease for both cancer and other conditions. The majority of studies were published
after 2010 and in high income countries. Few studies focused exclusively on the experience of living with comorbid conditions
alongside cancer; such that evidence was limited. Key themes identified included the interaction between cancer and comorbid
conditions, symptom experience, illness identities and ageing, self-management and the role of primary and secondary care.
Conclusions In addition to a better understanding of the complex experience of cancer and comorbidity, the review will combine
with research prioritisation work with consumers to inform an interview study with the defined patient group.
Implications for Cancer Survivors Expanding this evidence base will help to illuminate developing models of cancer patient-
centred follow-up care for the large proportion of patients with comorbid conditions.
Keywords Comorbidity . Systematic review . Qualitative . Supportive care . Cancer experience . Survivorship care
Introduction
Macmillan Cancer Support estimates that there are now 2.5
million people living with and beyond cancer in the UK, and
this figure is expected to rise to 4 million by 2030 [1], ex-
plained, in part, by the ageing population, and improved
screening, earlier diagnosis and better treatments. Deborah
Boyle insightfully described the changing ‘cancer patient mo-
saic’, and the reality is that most people living beyond cancer
are living with additional comorbid illness [2]. As many as
78% of cancer patients report at least one other condition, and
such multi-morbidity also increases with age [3, 4]. A recent
study suggested that cancer survivors had an average of five
comorbid conditions, with some of these developing after
cancer diagnosis [5]. Commonly reported comorbid condi-
tions among cancer survivors included heart- and lung-
related illnesses, ear and eye problems, hypertension, arthritis
or rheumatism and depression and anxiety [5, 6]. Prevalence
and comorbidity type varied according to time since diagnosis
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and cancer type, as well as associations with ethnicity, marital
status, weight and physical activity [5]. Evidence suggests that
the presence of comorbid conditions among those diagnosed
with cancer is associated with poorer survival and quality of
life, due to increased symptom burden, being less likely to
receive treatment with curative intent and these patients are
often excluded from clinical trials [7].
Psychosocial support for cancer survivors has become an
increasing priority on the policy agenda over the last 10 years,
as evidenced by a recent Lancet Oncology paper series devot-
ed to cancer survivorship [8]. In the UK, this policy priority
was set out in the Cancer Reform Strategy, which in turn led to
the development of the National Cancer Survivorship
Initiative in England and Wales [9, 10], and forms part of
the remit for Scotland’s Better Cancer Care [11].
Follow-up care and psychosocial support for survivors of
cancer presents challenges to health care services [12] and has
implications for the role of primary, secondary and communi-
ty care as newmodels of follow-up are recommended [13, 14].
This picture becomes more complex in the presence of comor-
bidities, with implications for the coordination of quality care
and support [15, 16]. While valuable research has been con-
ducted to understand the experience of living with and beyond
cancer for the patient [10, 17], and their relatives [18–22], less
is known about the impact of additional chronic illness.
Research exploring the support needs of people living with
multiple complex conditions, including cancer, therefore
needs to be identified [23]. Service development and provi-
sion would also benefit from insights in this area, in order to
highlight areas for further research [17, 24].
Aims and research questions
Understanding the challenges experienced by people living
after a cancer diagnosis with other chronic conditions such
as COPD, diabetes or mental ill health, can give new insights
into patient-centred models of care. A systematic review ap-
proach provides a comprehensive process to explore the cur-
rent evidence base and define a research agenda building on
prior knowledge [25]. This systematic review aimed to iden-
tify and synthesise qualitative evidence on the experience of
living with and beyond cancer with one or more additional
long-term illnesses. Insights from the review will inform fur-
ther research in this area. The review seeks to answer the
following questions:
& What qualitative evidence is available that explores the
experience of living with both cancer and one or more co-
morbidities from patient, carer and provider perspectives?
& What are the psychosocial support needs of people living
with cancer and one or more comorbidity as identified in
the literature?
& What are patient, carer and provider experiences of service
provision for cancer and comorbid conditions reported in
the literature and what research priorities can be derived
from the available evidence?
Methods
The reviewmethods are detailed in full in a published protocol
[26]. The methods are summarised below. The review proto-
col is registered on the International Prospective Register of
Systematic Reviews (PROSPERO) database (registration
number: CRD42016041796).
Design and ethics
A review of qualitative papers was chosen to fit with the aim
of exploring people’s experiences, using a person-centred ap-
proach to highlight context and generate meaningful and rel-
evant findings [27]. The review used methods of qualitative
synthesis to combine, integrate and interpret, where possible,
the evidence from the included papers [27, 28]. The review
aimed to move beyond the aggregation of available data to
provide further interpretive insights into living with complex
illness and define where future research can add to what is
known [28].
The review method follows the PRISMA statement guid-
ance for conducting a systematic review [29].
This review was exempt from NHS and internal University
of Edinburgh Usher Institute for Population Health Sciences
and Informatics Ethics Review Committee because no prima-
ry data was used.
Eligibility criteria
Articles were included if they were published in English be-
tween January 2000–January 2017 to capture the current sur-
vivorship agenda while allowing for a broad view of issues as
they have developed. Eligible articles included wholly quali-
tative studies and the qualitative component of mixedmethods
studies (including unpublished literature) addressing the topic
of psychosocial dimensions of living with cancer and comor-
bid illness (diagnosed before or after the cancer diagnosis but
not directly caused by the cancer), including issues of support
and experience of service provision from diagnosis to end of
life. Adult patients (18 years or over), informal carer and
health care professional perspectives were included.
Any cancer type was included along with any comorbidity
(as defined by the ISD Scotland report [30]) and listed in
Barnett et al.’s paper mapping the epidemiology of multi-
morbidity [4], listed in Online Resource 1. Long-term side
effects of cancer treatment and second primary cancers were
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not included. See Online Resource 2 for a summary of inclu-
sion and exclusion criteria.
Dimensions of interest
The review includes physical, social, emotional, psychologi-
cal and spiritual dimensions of experience of cancer and co-
morbidity. Full details of the review topic can be found in the
study protocol [26].
Information sources
Literature was identified using a variety of methods, including
database searching, citation and snowball searching, known
expert consultation via email and related articles searches in
PubMed and Google scholar. The databases consulted were
Medline, Embase, CINAHL, PsycINFO, ASSIA,
Sociological Abstracts, Web of Science, SCOPUS and, for
grey literature, OpenGrey and ProQuest Dissertations and
Theses Global.
Search strategy
A broad search strategy was developed to reflect the explor-
atory nature of the review (see Online Resource 3 for an
example search strategy for Medline, adapted to each
database using free text, MeSH and subject headings where
possible for maximum sensitivity and specificity).
Data collection and analysis
Study records and screening
Identified records were imported into EndNoteX7 and man-
aged in subsequent databases to track the number of records at
each stage of the screening process. Two reviewers (DC and
LH) screened articles in three stages: title, abstract and full
text. A third reviewer (CC) screened a proportion of articles
and discrepancies were discussed and resolved by the third
reviewer.
Quality assessment The Critical Appraisal Skills Programme
(CASP) tool was used to assess the quality of the included
studies as it was considered an appropriate tool for qualitative
studies and is widely used (www.casp-uk.net). DC, LH and
MD carried out critical appraisal and discussed any
discrepancies of one point or more on the 10-point scale.
The overall quality of the included studies was appraised as
good, with scores ranging from 5.5 to 10. A summary of the
quality appraisal is shown in Online Resource 4. No articles
were excluded on the basis of poor quality. Findings were
interpreted in the context of the quality markers and corre-
sponding limitations of the included studies.
Data extraction Data was extracted by DC and LH from in-
cluded studies into a Microsoft Excel proforma, including:
author; year of publication; country of study; study type; set-
ting; relevant background and impetus for the study; method-
ological approach and specified methods; patient characteris-
tics and demographics including cancer and comorbidity type;
main findings relating to illness experience, psychosocial
needs and supportive care; strengths and limitations and key
relevant discussion points.
Data synthesis Thematic synthesis, developed by Thomas and
Harden, was chosen as an appropriate, transparent method for
combining and interpreting qualitative findings [27, 28] (see
protocol for full details on the chosen approach) for a hetero-
geneous body of evidence. This method allowed comparison
of concepts and themes that relate different studies and uses a
similar approach to developing descriptive themes and an in-
terpretive account, as a grounded theory approach does with
primary data analysis [31, 32].
Patient and public involvement A consumer member of the
research team (EB) was involved in the design and implemen-
tation of the systematic review, commenting and helping to
shape the protocol and search strategy for the study, the syn-
thesis and the paper drafting.
Findings
Thirty-one articles were included in the final review [23,
33–62], based on 28 independent studies from an original
yield of 27,941 papers identified through searching, reference
snowballing, related articles and expert recommendation. The
full screening process is outlined in the PRISMA flowchart in
the PRISMA flow diagram (Fig. 1). The characteristics of the
31 included papers can be found in the characteristics of in-
cluded studies (Table 1).
The identified papers represented a heterogeneous range of
studies including different cancer and comorbidity types. The
majority of studies did not focus on the experience of cancer
and comorbidity. It was often the case that comorbid condi-
tions were mentioned briefly in relation to another issue, with
only small amounts of qualitative data and limited discussion
of specific issues relating to cancer and comorbidity. A small
number of studies focused mainly on the experience of comor-
bidity or multi-morbidity and cancer was considered tangen-
tially. Studies were largely exclusively qualitative, with five
mixed methods papers, and include three PhD theses.
Qualitative studies primarily used interviews (including lon-
gitudinal interviews), with a small number of focus group
studies and one paper including case studies and observations.
Two quantitative surveys included free-text comments.
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The majority of studies were published from 2010 on-
wards, with only five included studies published prior to this.
Papers were mostly published from high-income countries.
The majority were US-based, followed by the UK,
Germany, Sweden and Canada. Researchers came from a
number of different disciplines, settings and health systems,
all of which influence their approach, reporting style and thus
the extent to which the results can be synthesised.
Studies were mostly set in secondary care hospitals,
specialist clinics or specialist cancer centres; others includ-
ed primary and community care settings (not all studies
specified where participants were recruited from). The ma-
jority of studies included patient perspectives and two also
included informal carer interviews. Six studies included
health professional perspectives (two of these alongside
patient interviews): three primary care and three specialist
views.
Nine studies focused exclusively on breast cancer. Other
common cancers included were prostate, lung, colorectal
and lymphoma. Three studies did not specify a cancer type
whereas others non-specifically reported on ‘any’ cancer
type. Comorbid conditions were mostly reported in general
but three studies focused on exclusive conditions: diabetes,
dementia and depression. Common examples of other co-
morbid conditions featured were cardiac conditions includ-
ing hypertension, arthritis, chronic pain, lung/respiratory
conditions and stroke.
There was variation of stage and severity of cancer and/or
comorbid condition, and in time since original diagnosis (de-
pending on the aims and objectives of the included studies)
such that experience could be expected to vary considerably
depending on these characteristics, limiting opportunity for
synthesis. It was important to consider these variations when
interpreting differences in findings.
The total number of participants in a study ranged from five
to 1056 (free-text comments from a survey of 3300 [37].
Eleven papers looked at women only; the rest included both
men and women apart from one study with health profes-
sionals which did not specify gender. Experience of ageing
in the context of illness was a key issue (mentioned in 11
papers), although interpretation of ‘older’ varied considerably
from 50+ to 70+ with included participants in their late 90s so
experiences were likely to vary extensively.
Studies varied considerably in their reporting of theoret-
ical underpinnings and epistemology. Some described
analysis without referring to a theoretical or methodologi-
cal approach and only a few studies gave more detailed
accounts of their theoretical stance and the methodological
coherence.
Synthesis
Five themes emerged from the analysis. The themes relating to
each included study are listed in column 10 of Table 1.
Records idenﬁed through 
database searching
(n = 27930 )
Sc
re
en
in
g
In
clu
de
d
El
ig
ib
ili
ty
noitacifitnedI
Addional records idenfied 
through other sources
(n = 11 )
Records aer duplicates removed
(n = 23460 )
Records screened
(n = 23460 )
Records excluded
(n = 23358 ) not relevant
Full-text arcles assessed 
for eligibility
(n =  102 )
Full-text arcles excluded, 
with reasons
(n = 71 )
n=23 inappropriate:
conference abstract, 
review, non-English, 
quantave.
n=32 no clear combined 
focus on cancer and 
comorbid condion
n=16 no speciﬁc 
focus/data on experience
of cancer and comorbid 
condion(s) e.g. focus on 
intervenon or screening 
behaviour.
Studies included in 
qualitave synthesis
(n =  31)
Fig. 1 PRISMA flow diagram
J Cancer Surviv (2019) 13:148–159 151
Ta
bl
e
1
C
ha
ra
ct
er
is
tic
s
of
in
cl
ud
ed
st
ud
ie
s
A
ut
ho
r
(y
ea
r)
C
ou
nt
ry
of
st
ud
y/
se
tti
ng
St
ud
y
ty
pe
/m
et
ho
d
us
ed
St
ud
y
fo
cu
s
S
ub
je
ct
s/
ge
nd
er
(N
)
A
ge
of
su
bj
ec
ts
A
na
ly
si
s/
th
eo
re
tic
al
un
de
rp
in
ni
ng
s
re
po
rt
ed
C
an
ce
r
ty
pe
(y
ea
rs
si
nc
e
di
ag
no
si
s)
C
om
or
bi
d
ill
ne
ss
(e
s)
re
po
rt
ed
T
he
m
es
ev
id
en
ce
d
in
ar
tic
le
B
ak
er
[3
3]
20
15
U
SA
Q
L
/in
-d
ep
th
se
m
i-
st
ru
ct
ur
ed
in
te
rv
ie
w
s
at
tw
o
tim
e
po
in
ts
C
lin
ic
al
ca
re
pr
ov
id
er
s’
vi
ew
s
on
su
rv
iv
or
s’
w
ei
gh
tm
an
ag
em
en
t
Pr
of
es
si
on
al
s:
on
co
lo
gi
st
s,
su
rg
eo
ns
,P
C
Ps
,
nu
rs
es
,
di
et
ic
ia
ns
.
(N
=
33
)
?
C
on
st
an
tc
om
pa
ra
tiv
e
an
al
ys
is
Pr
os
ta
te
,b
re
as
t,
no
n-
H
od
gk
in
’s
ly
m
ph
om
a
(y
ea
rs
no
t
re
po
rt
ed
)
D
ia
be
te
s,
hy
pe
rt
en
si
on
1,
2,
4,
5
B
ar
tle
tt
[3
4]
20
12
U
K
Q
L
/in
-d
ep
th
in
te
rv
ie
w
s
H
ea
lth
pr
of
es
si
on
al
vi
ew
s
on
ne
ed
s
as
se
ss
m
en
ta
nd
co
m
m
un
ic
at
io
n
w
ith
ca
nc
er
pa
tie
nt
w
ith
de
m
en
tia
H
ea
lth
ca
re
pr
of
es
si
on
al
s
(N
=
5)
?
H
ei
de
gg
er
’s
ph
en
om
en
ol
og
ic
al
ap
pr
oa
ch
N
ot
re
po
rt
ed
;
pr
of
es
si
on
al
in
te
rv
ie
w
s
D
em
en
tia
1,
2,
3,
4,
5
B
ec
k
[3
5]
20
09
U
SA
M
ix
ed
/in
te
rv
ie
w
s
an
d
ps
yc
ho
m
et
ri
c
te
st
s
Sy
m
pt
om
ex
pe
ri
en
ce
,Q
oL
an
d
fu
nc
tio
na
l
pe
rf
or
m
an
ce
of
ca
nc
er
su
rv
iv
or
s
at
1
an
d
3
m
on
th
s
po
st
-t
re
at
m
en
t
M
al
e
an
d
fe
m
al
e
ca
nc
er
pa
tie
nt
s
(N
=
52
)
65
+
N
ot
re
po
rt
ed
A
ll—
m
os
tc
om
m
on
br
ea
st
an
d
pr
os
ta
te
(1
an
d
3
ye
ar
s
af
te
r
di
ag
no
si
s)
A
rt
hr
iti
s,
hy
pe
rt
en
si
on
,
di
ab
et
es
,h
ea
rt
di
se
as
e,
lu
ng
di
se
as
e,
ne
ur
om
us
cu
la
r
di
se
as
e
1,
2,
3,
5
C
la
rk
e
[3
6]
20
13
C
an
ad
a
Q
L
/s
em
i-
st
ru
ct
ur
ed
in
te
rv
ie
w
s
at
tw
o
tim
e
po
in
ts
E
xp
er
ie
nc
e
of
m
ul
tip
le
co
nd
iti
on
s
in
la
te
r
lif
e
an
d
in
fl
ue
nc
e
of
ge
nd
er
an
d
ag
e.
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
w
ith
m
ul
ti-
m
or
bi
di
ty
(N
=
35
)
73
+
Pa
tto
n’
s
th
em
at
ic
an
al
ys
is
N
ot
cl
ea
rl
y
re
po
rt
ed
(o
ne
bl
ad
de
r
ca
nc
er
)
A
rt
hr
iti
s,
ba
ck
pa
in
,h
ea
rt
di
se
as
e,
C
O
PD
1,
2,
3,
4
C
or
ne
r
[3
7]
20
13
U
K
M
ix
ed
/Q
L
fr
ee
te
xt
co
m
m
en
ts
an
al
ys
is
H
ow
fr
ee
te
xt
co
m
m
en
ts
on
PR
O
M
s
ad
de
d
to
un
de
rs
ta
nd
in
g
of
Q
oL
is
su
es
fo
r
su
rv
iv
or
s
M
al
e
an
d
fe
m
al
e
ca
nc
er
pa
tie
nt
s
(N
=
10
56
)
O
ve
r
16
C
on
te
nt
an
al
ys
is
B
re
as
tc
an
ce
r,
co
lo
re
ct
al
ca
nc
er
,n
on
-H
od
gk
in
ly
m
ph
om
a,
pr
os
ta
te
ca
nc
er
(1
–5
ye
ar
s)
H
yp
er
te
ns
io
n,
ar
th
ri
tis
,
os
te
op
or
os
is
,b
ac
k
pa
in
1,
2,
3,
4,
5
C
ou
rt
ie
r
[3
8]
20
16
U
K
Q
L
/c
as
e
st
ud
ie
s
O
ut
pa
tie
nt
ex
pe
ri
en
ce
s
of
pa
tie
nt
s
w
ith
de
m
en
tia
an
d
on
co
lo
gy
m
an
ag
em
en
t
M
al
e
an
d
fe
m
al
e
ca
nc
er
/d
em
en
tia
pa
tie
nt
s
an
d
fi
ve
H
C
Ps
(N
=
16
)
?
W
ol
co
tt’
s
fr
am
ew
or
k
fo
r
qu
al
ita
tiv
e
da
ta
an
al
ys
is
B
re
as
tc
an
ce
r,
pr
os
ta
te
ca
nc
er
,h
ea
d
an
d
ne
ck
ca
nc
er
s,
pe
lv
ic
ca
nc
er
,
co
lo
re
ct
al
(y
ea
rs
no
t
re
po
rt
ed
)
D
em
en
tia
1,
3,
4,
5
D
ah
lh
au
s
[3
9]
20
14
G
er
m
an
y
Q
L
/s
em
i-
st
ru
ct
ur
ed
te
le
ph
on
e
in
te
rv
ie
w
s
G
er
m
an
G
Ps
’
vi
ew
s
on
in
vo
lv
em
en
ti
n
pa
tie
nt
s’
ca
nc
er
ca
re
M
al
e
an
d
fe
m
al
e
G
Ps
(N
=
30
)
?
M
ay
ri
ng
’s
qu
al
ita
tiv
e
co
nt
en
ta
na
ly
si
s
A
ny
pr
of
es
si
on
al
in
te
rv
ie
w
s
D
em
en
tia
,h
yp
er
te
ns
io
n
5
Fe
nl
on
[4
0]
20
13
U
SA
Q
L
/in
-d
ep
th
se
m
i-
st
ru
ct
ur
ed
in
te
rv
ie
w
s
L
iv
ed
ex
pe
ri
en
ce
,s
up
po
rt
an
d
in
fo
rm
at
io
n
ne
ed
s
of
br
ea
st
ca
nc
er
pa
tie
nt
s
w
ith
co
m
or
bi
d
ill
ne
ss
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
(N
=
48
,
43
ar
e
m
al
e)
70
–9
0
ye
ar
s
B
ra
un
an
d
C
la
rk
e’
s
th
em
at
ic
an
al
ys
is
B
re
as
tc
an
ce
r
(u
p
to
10
ye
ar
s)
C
ar
di
ac
co
nd
iti
on
s,
ar
th
ri
tis
,h
yp
er
te
ns
io
n,
di
ab
et
es
1,
2,
3,
5
Fi
x
[4
1]
20
14
U
SA
Q
L
/lo
ng
itu
di
na
l
in
te
rv
ie
w
s
H
yp
er
te
ns
io
n
se
lf
-m
an
ag
em
en
ti
n
pa
-
tie
nt
s
w
ith
co
m
or
bi
di
tie
s
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
(N
=
48
,
43
ar
e
m
al
e)
M
ea
n
ag
e
60
ye
ar
s
G
ro
un
de
d
th
eo
ry
ap
pr
oa
ch
;K
le
in
m
an
’s
ex
pl
an
at
or
y
m
od
el
as
a
fr
am
ew
or
k
Pr
os
ta
te
ca
nc
er
,r
en
al
ca
nc
er
(y
ea
rs
no
t
re
po
rt
ed
)
H
yp
er
te
ns
io
n,
an
xi
et
y,
ar
th
ri
tis
,b
ac
k
pa
in
,
ca
rd
io
va
sc
ul
ar
di
se
as
e,
C
O
PD
,d
ep
re
ss
io
n,
gl
au
co
m
a,
Pa
rk
in
so
n’
s
di
se
as
e
1,
2,
4,
5
H
an
nu
m
[4
2]
20
16
U
SA
Q
L
/lo
ng
itu
di
na
l
in
te
rv
ie
w
s
N
ar
ra
tiv
es
of
ca
nc
er
am
on
g
ch
ro
ni
ca
lly
ill
ol
de
r
ad
ul
ts
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
(N
=
16
,
13
ar
e
fe
m
al
e)
65
an
d
ov
er
T
he
m
at
ic
an
al
ys
is
ba
se
d
on
sy
m
bo
lic
in
te
ra
ct
io
ni
sm
,
B
re
as
t,
co
lo
n,
br
ai
n,
en
do
m
et
ri
al
,
oe
so
ph
ag
ea
l,
G
IS
T,
la
rg
e
B
ce
ll
D
ia
be
te
s,
gl
au
co
m
a
2,
3
152 J Cancer Surviv (2019) 13:148–159
T
ab
le
1
(c
on
tin
ue
d)
A
ut
ho
r
(y
ea
r)
C
ou
nt
ry
of
st
ud
y/
se
tti
ng
St
ud
y
ty
pe
/m
et
ho
d
us
ed
St
ud
y
fo
cu
s
Su
bj
ec
ts
/g
en
de
r
(N
)
A
ge
of
su
bj
ec
ts
A
na
ly
si
s/
th
eo
re
tic
al
un
de
rp
in
ni
ng
s
re
po
rt
ed
C
an
ce
r
ty
pe
(y
ea
rs
si
nc
e
di
ag
no
si
s)
C
om
or
bi
d
ill
ne
ss
(e
s)
re
po
rt
ed
T
he
m
es
ev
id
en
ce
d
in
ar
tic
le
co
ns
tr
uc
tiv
is
m
an
d
ph
en
om
en
ol
og
y
ly
m
ph
om
a,
pa
nc
re
at
ic
,s
to
m
ac
h
(w
ith
in
1
ye
ar
)
H
er
sh
ey
[4
3]
20
12
U
SA
M
ix
ed
/p
ho
ne
su
rv
ey
w
ith
tw
o
op
en
-e
nd
ed
qu
es
-
tio
ns
Im
pa
ct
of
ca
nc
er
an
d
its
tr
ea
tm
en
to
n
di
ab
et
es
se
lf
-m
an
ag
em
en
t
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
(N
=
37
)
50
an
d
ov
er
Q
ua
lit
at
iv
e
co
nt
en
t
an
al
ys
is
B
re
as
t,
lu
ng
an
d
pa
nc
re
as
(y
ea
rs
no
tr
ep
or
te
d)
D
ia
be
te
s
(t
yp
e
I
an
d
II
)
1,
2,
3,
4,
5
K
an
ts
ip
er
[4
4]
20
09
U
SA
Q
L
/f
oc
us
gr
ou
p
in
te
rv
ie
w
s
N
ee
ds
an
d
pr
io
ri
tie
s
of
br
ea
st
ca
nc
er
pa
tie
nt
s,
on
co
lo
gi
st
s
an
d
PC
Ps
.
Fe
m
al
e
pa
tie
nt
s;
m
al
e
an
d
fe
m
al
e
pr
of
es
si
on
al
s
(N
=
52
)
?
Q
ua
lit
at
iv
e
th
em
at
ic
an
al
ys
is
B
re
as
t(
1
ye
ar
or
m
or
e)
D
ia
be
te
s,
hy
pe
rt
en
si
on
,
re
na
li
ss
ue
s
5
L
oe
rz
el
[4
5]
20
12
U
SA
Q
L
/s
em
i-
st
ru
ct
ur
ed
in
te
rv
ie
w
s
U
nd
er
st
an
di
ng
po
st
-t
re
at
m
en
ts
ur
vi
vo
r-
sh
ip
in
ol
de
r
w
om
en
w
ith
br
ea
st
ca
nc
er
Fe
m
al
e
pa
tie
nt
s
(N
=
20
)
65
–8
6
ye
ar
s
G
ro
un
de
d
th
eo
ry
ap
pr
oa
ch
an
d
an
al
ys
is
B
re
as
t(
w
ith
in
1
ye
ar
)
Fi
br
om
ya
lg
ia
,a
rt
hr
iti
s
1,
2,
3
L
oe
rz
el
[4
6]
20
13
U
SA
Q
L
/s
em
i-
st
ru
ct
ur
ed
in
te
rv
ie
w
s
U
nd
er
st
an
di
ng
po
st
-t
re
at
m
en
ts
ur
vi
vo
r-
sh
ip
in
ol
de
r
w
om
en
w
ith
br
ea
st
ca
nc
er
Fe
m
al
e
pa
tie
nt
s
(N
=
20
)
65
–8
6
ye
ar
s
G
ro
un
de
d
th
eo
ry
ap
pr
oa
ch
an
d
an
al
ys
is
B
re
as
t(
w
ith
in
1
ye
ar
)
Fi
br
om
ya
lg
ia
,a
rt
hr
iti
s
2,
3
M
as
on
[2
3]
20
14
U
K
Q
L
/in
-d
ep
th
se
ri
al
in
te
rv
ie
w
s
E
xp
er
ie
nc
e
of
ad
va
nc
ed
m
ul
ti-
m
or
bi
di
ty
an
d
im
-
pl
ic
at
io
ns
fo
r
pa
lli
at
iv
e
an
d
en
d
of
lif
e
ca
re
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
an
d
ca
re
rs
(N
=
37
)
55
–6
2
ye
ar
s
(m
ea
n
76
)
T
he
m
at
ic
an
al
ys
is
;
co
ns
tr
uc
tio
ni
st
ap
pr
oa
ch
L
un
g
(y
ea
rs
no
tr
ep
or
te
d)
H
ea
rt
di
se
as
e,
re
sp
ir
at
or
y,
liv
er
,r
en
al
fa
ilu
re
,
ne
ur
ol
og
ic
al
co
nd
iti
on
s,
de
m
en
tia
2,
3,
4,
5
M
or
ga
n
[4
7]
20
15
U
K
Q
L
/in
-d
ep
th
se
ri
al
in
te
rv
ie
w
s
E
xp
er
ie
nc
e
of
ad
va
nc
ed
m
ul
ti-
m
or
bi
di
ty
an
d
im
-
pl
ic
at
io
ns
fo
r
pa
lli
at
iv
e
an
d
en
d
of
lif
e
ca
re
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
an
d
ca
re
rs
(N
=
37
)
55
–6
2
ye
ar
s
(m
ea
n
76
)
T
he
m
at
ic
an
al
ys
is
;
co
ns
tr
uc
tio
ni
st
ap
pr
oa
ch
B
re
as
t;
pr
of
es
si
on
al
in
te
rv
ie
w
s
D
em
en
tia
an
d
ot
he
rs
no
n-
sp
ec
if
ie
d
1,
5
N
an
to
n
[4
8]
20
16
U
K
Q
L
/in
-d
ep
th
se
ri
al
in
te
rv
ie
w
s
To
ex
am
in
e
th
e
im
pa
ct
of
un
ce
rt
ai
nt
y
on
id
en
tit
y
in
pe
op
le
w
ith
ad
va
nc
ed
m
ul
ti-
m
or
bi
di
ty
an
d
th
e
ro
le
of
H
C
Ps
an
d
he
al
th
sy
st
em
s
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
an
d
ca
re
rs
(N
=
37
)
41
–9
2
ye
ar
s
T
he
m
at
ic
an
al
ys
is
;b
as
ed
on
so
ci
al
co
ns
tr
uc
tio
ni
sm
an
d
et
hn
og
ra
ph
y
L
un
g,
pr
os
ta
te
(y
ea
rs
no
t
re
po
rt
ed
)
St
ro
ke
,i
sc
ha
em
ic
he
ar
t
di
se
as
e,
de
m
en
tia
,
os
te
oa
rt
hr
iti
s,
hy
pe
rt
en
si
on
2,
3,
4,
5
N
or
m
an
[4
9]
20
01
C
an
ad
a
Q
L
/s
em
i-
st
ru
ct
ur
ed
in
te
rv
ie
w
s
Pa
lli
at
iv
e
ca
re
pa
tie
nt
s’
re
la
tio
ns
hi
ps
w
ith
th
ei
r
fa
m
ily
ph
ys
ic
ia
ns
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
(N
=
25
)
28
–8
4
ye
ar
s
G
ro
un
de
d
th
eo
ry
ap
pr
oa
ch
12
ty
pe
s
of
ca
nc
er
(1
m
on
th
-1
2
ye
ar
s)
D
ia
be
te
s
5
Pa
lm
er
[5
0]
20
11
U
SA
M
ix
ed
/s
ur
ve
y
an
d
in
te
rv
ie
w
s
H
ea
lth
-r
el
at
ed
go
al
s
of
po
st
-t
re
at
m
en
tc
ol
or
ec
ta
l
ca
nc
er
su
rv
iv
or
s
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
(N
=
41
)
33
–8
7
ye
ar
s
U
nc
le
ar
;t
he
m
at
ic
an
al
ys
is
de
sc
ri
be
d
C
ol
or
ec
ta
l(
w
ith
in
2
ye
ar
s)
D
ia
be
te
s,
ch
ro
ni
c
pa
in
2,
3,
4
Pa
lm
er
[5
1]
20
13
U
SA
Q
L
/s
em
i-
st
ru
ct
ur
ed
in
te
rv
ie
w
s
H
ea
lth
-r
el
at
ed
go
al
s
of
po
st
-t
re
at
m
en
tc
ol
or
ec
ta
l
ca
nc
er
su
rv
iv
or
s
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
(N
=
41
)
33
–8
7
ye
ar
s
C
on
te
nt
an
al
ys
is
C
ol
or
ec
ta
l(
w
ith
in
2
ye
ar
s)
D
ia
be
te
s,
ch
ro
ni
c
pa
in
2,
4
Sa
da
[5
2]
20
11
U
SA
Q
L
/s
em
i-
st
ru
ct
ur
ed
in
te
rv
ie
w
s
PC
P
an
d
on
co
lo
gi
st
s’
ro
le
s
an
d
co
m
m
un
ic
at
io
n
in
M
al
e
pa
tie
nt
s,
m
al
e
an
d
fe
m
al
e
40
–8
0+
U
nc
le
ar
;s
om
e
fo
rm
of
th
em
at
ic
an
al
ys
is
C
ol
or
ec
ta
l(
w
ith
in
2
ye
ar
s)
C
O
PD
,c
ar
di
ov
as
cu
la
r
di
se
as
e,
di
ab
et
es
an
d
ot
he
rs
no
n-
sp
ec
if
ie
d
1,
2,
3,
4,
5
J Cancer Surviv (2019) 13:148–159 153
T
ab
le
1
(c
on
tin
ue
d)
A
ut
ho
r
(y
ea
r)
C
ou
nt
ry
of
st
ud
y/
se
tti
ng
St
ud
y
ty
pe
/m
et
ho
d
us
ed
St
ud
y
fo
cu
s
Su
bj
ec
ts
/g
en
de
r
(N
)
A
ge
of
su
bj
ec
ts
A
na
ly
si
s/
th
eo
re
tic
al
un
de
rp
in
ni
ng
s
re
po
rt
ed
C
an
ce
r
ty
pe
(y
ea
rs
si
nc
e
di
ag
no
si
s)
C
om
or
bi
d
ill
ne
ss
(e
s)
re
po
rt
ed
T
he
m
es
ev
id
en
ce
d
in
ar
tic
le
sh
ar
ed
ca
re
of
ca
nc
er
pa
tie
nt
s
pr
of
es
si
on
al
s
(N
=
24
)
Sa
un
de
rs
-S
tu
rm
[3
1]
20
03
U
SA
Q
L
/s
em
i-
st
ru
ct
ur
ed
in
te
rv
ie
w
s
L
iv
ed
ex
pe
ri
en
ce
of
br
ea
st
ca
nc
er
Fe
m
al
e
pa
tie
nt
s
(N
=
33
)
47
ye
ar
s
an
d
ov
er
G
ro
un
de
d
th
eo
ry
ap
pr
oa
ch
;s
oc
ia
l
co
ns
tr
uc
tio
ni
st
B
re
as
t
(1
8
m
on
th
s-
4
ye
ar
s)
A
rt
hr
iti
s,
as
th
m
a,
ch
ro
ni
c
br
on
ch
iti
s,
hi
gh
bl
oo
d
pr
es
su
re
an
d
di
ab
et
es
2,
3,
4
Sa
w
in
[5
4]
20
12
U
SA
Q
L
/s
em
i-
st
ru
ct
ur
ed
in
te
rv
ie
w
s
A
ge
in
g
re
la
te
d
ex
pe
ri
en
ce
s
of
w
om
en
w
ith
br
ea
st
ca
nc
er
in
un
su
pp
or
tiv
e
re
la
tio
ns
hi
ps
Fe
m
al
e
pa
tie
nt
s
(N
=
16
)
50
–8
4
ye
ar
s
(m
ea
n
68
.1
)
H
er
m
en
eu
tic
ph
en
om
en
ol
og
ic
al
an
al
ys
is
B
re
as
t(
1–
31
ye
ar
s;
m
ea
n
7.
4)
H
yp
er
te
ns
io
n,
ch
ro
ni
c
pa
in
,C
O
PD
1,
2,
3
Si
nd
in
g
[5
5]
20
08
C
an
ad
a
Q
L
/s
em
i-
st
ru
ct
ur
ed
in
te
rv
ie
w
s
at
tw
o
tim
e
po
in
ts
O
ld
er
w
om
en
’s
ex
pe
ri
en
ce
s
of
ca
nc
er
Fe
m
al
e
pa
tie
nt
s
(N
=
15
)
70
ye
ar
s
an
d
ov
er
G
ro
un
de
d
th
eo
ry
ap
pr
oa
ch
an
d
an
al
ys
is
B
re
as
ta
nd
gy
na
ec
ol
og
ic
al
(w
ith
in
3
ye
ar
s)
D
ia
be
te
s,
C
hr
oh
n’
s
di
se
as
e,
‘m
en
ta
l
ill
ne
ss
’
1,
2,
3
So
w
er
bu
tts
[5
6]
20
15
U
K
Q
L
/in
-d
ep
th
in
te
rv
ie
w
s
Su
rg
er
y
de
ci
si
on
s
in
ol
de
r
w
om
en
w
ith
br
ea
st
ca
nc
er
Fe
m
al
e
pa
tie
nt
s
(N
=
28
)
70
–9
9
ye
ar
s
Fr
am
ew
or
k
an
al
ys
is
B
re
as
t(
w
ith
in
30
da
ys
)
N
on
-s
pe
ci
fi
ed
1,
3,
5
T
ho
m
é
[5
7]
20
03
Sw
ed
en
Q
L
/in
te
rv
ie
w
s
E
xp
er
ie
nc
es
of
ol
de
r
pe
op
le
liv
in
g
w
ith
ca
nc
er
an
d
its
im
pa
ct
on
da
ily
lif
e
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
(N
=
64
)
76
–9
9
ye
ar
s
(m
ea
n
87
)
L
at
en
tc
on
te
nt
an
al
ys
is
B
re
as
t,
pr
os
ta
te
,g
as
tr
o,
gy
na
e,
ur
og
en
ita
l,
sk
in
,
lu
ng
/la
ry
nx
,
ha
em
at
ol
og
ic
al
W
ith
in
5
ye
ar
s
1,
2,
3,
4
V
ol
ke
r
[5
8]
20
13
U
SA
Q
L
/f
oc
us
gr
ou
p
in
te
rv
ie
w
s
C
an
ce
r
di
ag
no
si
s
fo
r
pe
op
le
w
ith
pr
e-
ex
is
tin
g
fu
nc
-
tio
na
ll
im
ita
tio
ns
an
d
to
pi
cs
fo
r
a
w
el
ln
es
s
in
te
r-
ve
nt
io
n
pr
og
ra
m
m
e
Fe
m
al
e
pa
tie
nt
s
(N
=
19
)
21
an
d
ov
er
(m
ea
n
59
.5
)
Pa
tto
n’
s
qu
al
ita
tiv
e
co
nt
en
ta
na
ly
si
s
B
re
as
t,
co
lo
re
ct
al
,
bl
ad
de
r,
gy
na
e,
m
el
an
om
a,
th
yr
oi
d,
ki
dn
ey
(1
0
ye
ar
s
on
av
er
ag
e)
A
rt
hr
iti
s,
m
ul
tip
le
sc
le
ro
si
s
1,
2,
3,
4,
5
W
al
la
ce
[5
9]
20
15
U
SA
Q
L
/s
em
i-
st
ru
ct
ur
ed
in
te
rv
ie
w
s
at
tw
o
tim
e
po
in
ts
T
re
at
m
en
te
xp
er
ie
nc
es
of
ne
w
ly
di
ag
no
se
d
he
ad
an
d
ne
ck
ca
nc
er
pa
tie
nt
s
an
d
in
fl
ue
nc
e
of
ag
e
an
d
tim
e
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
(N
=
41
,
32
ar
e
m
al
e)
45
–9
1
(m
ea
n
58
.4
)
C
re
ss
w
el
l’s
qu
al
ita
tiv
e
an
al
ys
is
;b
as
ed
on
so
ci
o-
em
ot
io
na
ls
e-
le
ct
iv
e
th
eo
ry
an
d
L
ev
en
th
al
’s
se
lf
-r
eg
ul
at
io
n
m
od
el
H
ea
d
an
d
ne
ck
(w
ith
in
2
w
ee
ks
)
H
ea
rt
di
se
as
e,
di
ab
et
es
,
A
lz
he
im
er
’s
,C
O
PD
,
ar
th
ri
tis
,f
ib
ro
m
ya
lg
ia
,
liv
er
fa
ilu
re
3,
4,
5
W
im
be
rl
ey
[6
0]
20
12
U
SA
Q
L
/in
-d
ep
th
se
ri
al
in
te
rv
ie
w
s
In
fl
ue
nc
e
of
br
ea
st
ca
nc
er
on
w
om
en
’s
m
ea
ni
ng
s,
un
de
rs
ta
nd
in
g
an
d
se
lf
-i
de
nt
iti
es
ov
er
tim
e.
Fe
m
al
e
pa
tie
nt
s
(N
=
15
)
41
–7
6
ye
ar
s
(m
ea
n
59
.4
)
H
er
m
en
eu
tic
an
al
ys
is
;
ph
en
om
en
ol
og
ic
al
un
de
rp
in
ni
ng
s
B
re
as
t(
5–
25
ye
ar
s)
Sc
le
ro
de
rm
a
an
d
hy
po
th
yr
oi
di
sm
1,
2,
3,
4
Y
oo
[6
1]
20
10
U
SA
Q
L
/in
-d
ep
th
in
te
rv
ie
w
s
Ps
yc
ho
so
ci
al
im
pa
ct
of
br
ea
st
ca
nc
er
an
d
so
ci
al
su
pp
or
t
fo
r
ol
de
r
w
om
en
Fe
m
al
e
pa
tie
nt
s
(N
=
47
)
65
–8
3
ye
ar
s
G
ro
un
de
d
th
eo
ry
ap
pr
oa
ch
an
d
an
al
ys
is
B
re
as
t(
w
ith
in
4
ye
ar
s)
H
ea
rt
di
se
as
e
an
d
ot
he
rs
no
n-
sp
ec
if
ie
d
1,
2,
3,
4
Z
ha
ng
[6
2]
20
15
U
SA
M
ix
ed
/p
sy
ch
om
et
ri
c
te
st
an
d
in
te
rv
ie
w
s
U
ni
ve
rs
al
an
d
un
iq
ue
de
pr
es
si
ve
sy
m
pt
om
s
in
A
fr
ic
an
A
m
er
ic
an
ca
nc
er
pa
tie
nt
s
M
al
e
an
d
fe
m
al
e
pa
tie
nt
s
(N
=
74
)
M
ea
n
62
ye
ar
s
U
nc
le
ar
;t
he
m
at
ic
an
al
ys
is
de
sc
ri
be
d
N
ot
re
po
rt
ed
D
ep
re
ss
io
n
2
154 J Cancer Surviv (2019) 13:148–159
Interaction and impact of cancer and comorbidity
The interaction of having cancer and additional chronic illness
reportedly produces a complex and increased burden of ill
health for many,
‘They're morbidly obese, they have heart disease, diabe-
tes, they all have orthopedic issues... breast cancer's just
one thing’. (Nurse navigator, [33])
There is an indication in the literature reviewed that this com-
plexity influences not only quality of life, and recovery (e.g.
Corner et al. [37]), but also treatment decisions,
‘I could not have [general anaesthetic] because it affects
my heart, you see’. (Patient 23, [56])
‘If you have got umm a person with reduced mental
capacity [because of dementia] living on their own then
the safety of giving chemotherapy is a risk’ .
(Oncologist, [38])
Symptom experience
Related to interaction and impact of cancer and comorbidity,
experiencing additional chronic ill health as well as cancer
brought about a complex symptom burden that appeared to
be mediated by stage and severity as well as proximity to
diagnosis of the cancer and/or comorbidity. Evidence varied
to suggest that some patients prioritised one condition over
another; whereas, for others, they appeared to be entwined.
Participants in some studies described cancer as merely a
‘bump in the road’; whereas, for others, the symptoms and
effects were more enduring. For some, complexity of disease
led to a blurring of symptoms and an inability to attribute
symptomology to a particular condition; a source of fear of
the cancer returning,
‘Dr C said that he doesn't really feel that I got too much
to worry about, that they got it in time, but then how do
they know if they got everything? ...Andwhenmy lungs
are bad [asthma], it frightens you’. (Judith, [55])
Illness expectations and identity
Ability to adjust and cope with a complex burden of ill health
was influenced by past experience of illness (including se-
quencing of conditions, i.e. whether the cancer or the comor-
bid condition came first) as well as notions of ageing and
expectations of ailing health and functional ability.
Expecting illness with advancing age helped to ‘lessen the
shock’ of cancer diagnosis for some participants in the
included studies [45], captured by those participating in
Mason et al as ‘old not ill’ [23].
Maintaining a sense of control and one’s existing personal
identity appeared to be an important part of illness experience
for participants in many included studies,
‘One feels sorry for oneself, in the sense that one loses
one's independence and you become dependent on
others’. (91 year old patient with back problems, cancer,
heart disease and other conditions, [36])
Managing medications and self-management
A smaller number of studies referred to managingmedications
as being a challenge for people living with cancer and other
chronic illness at the same time. In addition to issues such as
being refused trial participation due to contraindicated medi-
cations and the financial cost of medications in relevant health
systems, one of the concerns raised was the ability to self-
manage the range of medications needed. Patients also had
to look out for contraindications as the communication be-
tween primary and secondary care or between different spe-
cialists was not always optimal, meaning the patient often had
to champion their position,
‘The fact that I'm on this pain control regimen, doctors
wanted to ignore it, he didn't want to deal with someone
on Fentnyl patch and Oxycodone, just didn't want to deal
with that. So if you don't advocate for yourself, forget
it...sometimes you get tired of fighting for yourself and
trying to educate everybody’. (Cancer patient, [58])
In terms of self-management, studies emphasised the need for
shared care or supported self-management (including looking
after overall health and well-being), and the need for resources
to enable this and to take the pressure off primary care in
providing follow-up care and support for this patient group.
Role of primary and secondary care
The evidence suggests that oncologists do not often see the
management of comorbid conditions as being part of their role
or within their perceived level of competency. GPs were more
likely to regard holistic condition management as part of their
role and advocated a patient-centred ‘joined up’ approach. For
example, a medical oncologist interviewed by Sada et al. said:
‘I encourage patients to continue the management of
their [chronic illness] with their PCP...I'm so
subspecialised that I don't really feel comfortable man-
aging [it]’. (Medical oncologist 6, [52])
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However, primary care practitioners did not always feel comfort-
ablemanaging advanced cancer symptoms, potentially leading to
a fragmented experience of care, as another study suggests:
‘[The FP (family physician) is] still looking after their
diabetes…One kind of doctor does this; he does that:
[to] each their own. Symptom control is not in their
hands…You leave that to the specialists. She’s just a
family physician’. (Cancer patient, [49]).
Managing cancer multi-morbidity in primary care carries
many challenges:
‘…Actually most of our patients have five or six issues,
and so we’re trying to manage their diabetes or hyper-
tension or renal insufficiency and then end up with a
breast issue, and it’s impossible…that’s like more than
an hour’s worth of time where you have like four pa-
tients scheduled in 15-min increments, and it’s over-
whelming’. (Primary Care Professional, [44])
Discussion
Summary
This systematic review of the evidence relating to the experi-
ence of living with and beyond cancer with comorbid illness
identified a small number of heterogeneous papers with a
range of aims and perspectives. Qualitative data on this spe-
cific topic was difficult to identify as comorbidities were often
mentioned in passing or ‘buried’ in articles with a different
dominant focus. From the 31 included studies, a number of
themes emerged to give a summary of the current evidence
and help identify topics for further investigation (see Fig. 2).
These issues relate to the burden of symptoms, the combined
impact on one’s illness experience and how adjustment was
entwined with previous experience of illness, illness expecta-
tions and the severity of the illness burden. Dealing with
polypharmacy, self-managing and the related challenges and
demand for health services, including the relationship between
primary and specialist care, were also identified as important
concerns. Overall, there is need to grow the evidence base on
this topic, in order to address the support needs of the growing
number of cancer survivors living with other chronic condi-
tions, their informal carers and health care professionals.
Place in the wider literature
The findings from the review sit within a wider literature ex-
amining experiences of cancer survivors and the role for pri-
mary and secondary care, as well as literature around multi-
morbidity, e.g. [20, 63–68]. There have been a number of
intervention studies to support patients living with and beyond
cancer [69, 70], and to consider the views of health care pro-
viders [21, 71]. There is also a recognition that guidance is
needed for a model of survivorship care that acknowledges the
challenges for and complexity of this patient group, including
measuring comorbid conditions and managing them in the
treatment and survivorship contexts [12, 13, 72].
A number of potential theoretical positions may provide in-
sight to the emergent themes from the synthesis. Indeed, a small
number of included studies refer to theory in order tomake sense
of their findings. For example, issues of symptom burden and
people’s illness expectations and identity relate to experience of
illness theory around keeping illness at the boundaries of one’s
self concept in an attempt to maintain one’s existing personal
identity (Charmaz 2000) and can be understood in the context of
biographical disruption, flow and continuity [73, 74] and
Frank’s illness narratives [75]. Further in-depth research can
revisit the potential contribution of these theoretical insights to
the experience of cancer and comorbid illness.
The issue of the pressure on primary care to manage cancer
survivor follow-up and for patients to self-manage is one that
has been problematised in the sociological literature, marking
a shift toward ‘living with and beyond cancer’. It is argued
that the term ‘survivor’ is heavily loaded with expectations of
optimism in ‘fighting’ the cancer battle with an emphasis on
individual responsibility and accountability for lifestyle
change and secondary prevention [76, 77], with implications
for the ‘burden of treatment’ work expected of patients and
their families, and with repercussions for health services [78].
Strengths and limitations
This review brings together studies exploring experience of
illness. It focuses on qualitative findings to meet the aims of
identifying contextual evidence of psychosocial issues and
supportive care needs.
The articles included in the review come from differing
settings and foci. Due to the broad exploratory nature of the
topic, it was difficult to design a search strategy that was
sensitive and specific. Given the ‘snippets’ of qualitative data
relating to the topic of cancer and comorbid illness, there may
be additional articles containing relevant data that were not
identified. Additional methods of snowball referencing and
related articles searching as well as expert consultation were
undertaken to address this potential limitation. Also, despite
the heterogeneity of the studies, it was possible to deduce
some common themes, suggesting that a diverse sample of
papers from a number of different settings can enable a level
of conceptual saturation of ideas [79], and remains true to the
aim of producing an abstract synthesis that is ‘faithful to the
group of studies from which it was extracted’ [80].
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The research agenda
While multi-morbidity in cancer survivors is often highlighted
as a key issue in literature and policy, qualitative research to
date has yet to focus on it as a substantive concern. Reviewing
the qualitative evidence on this topic has identified key themes
that warrant further exploration and focus. Variations in symp-
toms burden and the interaction and impact on one’s illness
experience have been indicated in the included studies.
Further, qualitative work is needed to explore the influence of
stage of survivorship, severity of the concomitant illnesses and
the meaning attributed to cancer in relation to other chronic
conditions. The challenges for health services have been iden-
tified in the literature: there is a call for further work to better
understand the difficulties facing primary and secondary care in
managing survivorship care in the context of multi-morbidity
and what patients want from services in this context. Finally,
carers’ views have been largely under-represented and it is im-
portant to explore the additional strain that caring for someone
with cancer and additional chronic conditions imposes. These
issues have also emerged from research prioritisation work car-
ried out by the authors in relation to this topic (in draft), as well
as the wider context of the recent National Cancer Research
Institute Top 10 research priorities for living with and beyond
cancer (www.NCRI.org.uk/lwbc), and have combined to
inform the design (including aims, sampling decisions and
interview topic guide) of an in-depth, multi-perspective inter-
view study with patients, carers and health care professionals.
Conclusions
Further, qualitative evidence is required to understand better
symptom experience, stage, severity and proximity to
diagnosis of disease, views on and experiences of current care,
support for self-management and the role of primary and sec-
ondary care, as well as carer experiences, to develop optimal
care for the complex needs of this growing and diverse group
of cancer survivors.
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